Jeffrey Bradley named interim chair of Emory Department of Radiation Oncology

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Jeffrey Bradley was named interim chairman of the Emory University Department of Radiation Oncology.

Bradley, previously the executive vice chairman of the department, succeeds former Winship Cancer Institute Executive Director Walter J. Curran, Jr., who announced in October 2020 that he would be stepping down from his role as chair (The Cancer Letter, Jan 22, 2021).

Bradley joined Winship in 2019 from Washington University School of Medicine in St. Louis where he was the S. Lee Kling Endowed Professor of Radiation Oncology and clinical director of the Kling Proton Center.

Bradley led the effort to open the world’s first single-room proton center at Washington University’s Barnes-Jewish Hospital. He is a founding member of the Particle Therapy Oncology Group of North America and the chairman of the NRG Oncology Lung Cancer Committee.

Since joining Winship, Bradley has been appointed the James W. Keller, MD Distinguished Professorship in Radiation Oncology in support of his research in innovative radiation therapy technologies such as proton beam therapy and stereotactic body radiation therapy.

Curran was chairman of the Department of Radiation Oncology for 13 years. He led efforts to open the Emory Proton Therapy Center, exclusively operated by department faculty and staff, which treated over 400 patients in its first year, and expanded basic, translational, and clinical research during his tenure.

In mid-January, the Department of Radiation Oncology appointed Curran as professor emeritus.

Table of Contents

YOU MAY BE INTERESTED IN

For nearly 25 years, business executive Lou Weisbach and urologist Richard J. Boxer have argued that finding the money to finance the cures for devastating diseases is not as difficult as it appears. To start finding the cures, the U.S. Department of the Treasury needs to issue some bonds—$750 billion worth. Next, you hire CEOs—one...

There is general agreement that the United States spends too much on health care, especially on pharmaceuticals.  But what we spend on drugs is not simply a function of price. If eggs double in price, people can simply cut the number of eggs they eat in half.  Simply stated, cost is the product of (price per unit times the number of units purchased). 
What did President Richard M. Nixon and Senator Edward M. Kennedy have in common? They each played a pivotal role in the passage of the National Cancer Act signed by Nixon on Dec. 23, 1971. The NCA established the National Cancer Program authorizing the initial investment in the NCI-designated Cancer Centers Program. 
When I first proposed targeting PCNA (proliferating cell nuclear antigen) as a therapeutic approach, the response I got was: “No one will ever make a drug against PCNA. It’s undruggable.” The protein lacks enzymatic activity, has a disordered region, and binds to over 200 other proteins within the cell. From a traditional drug development perspective, these characteristics made PCNA an impossible target.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login